» Articles » PMID: 2221859

Bactericidal Effect of Doxycycline Associated with Lysosomotropic Agents on Coxiella Burnetii in P388D1 Cells

Overview
Specialty Pharmacology
Date 1990 Aug 1
PMID 2221859
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

There is no consistently reliable treatment for endocarditis resulting from chronic Coxiella burnetii infection, the causative agent of Q fever. Although certain antibiotics are recommended on the basis of their in vitro bactericidal activities, results of therapy with these antibiotics are often disappointing. To evaluate whether the currently recommended antibiotic susceptibility tests for C. burnetii give misleading results because of continued division of uninfected cells, thereby resulting in the dilution of infected cells and, hence, a false picture of antibiotic efficacy, we blocked cell division during antibiotic susceptibility testing with cycloheximide. Using this new method, we found that the currently recommended antibiotics for the treatment of Q fever, doxycycline, pefloxacin, and rifampin, did not reduce the ratio of infected to noninfected cells (either L929 or P388D1) by 9 days postinfection. To test the hypothesis that this lack of antibacterial activity is due to antibiotic inactivation by the low pH of the phagolysosomes in which C. burnetii is found, we used alkalinizing lysosomotropic agents (chloroquine or amantadine) concurrently with doxycycline. This resulted in the sterilization of C. burnetii infection in P388D1 cells. This finding seems to confirm our suspicion that the acidic conditions of the phagolysosomes in which C. burnetii is located inhibit antibiotic activity. This inhibition can be reversed in vitro when lysosomotropic alkalinizing agents are used.

Citing Articles

Macrophages inhibit Coxiella burnetii by the ACOD1-itaconate pathway for containment of Q fever.

Kohl L, Siddique M, Bodendorfer B, Berger R, Preikschat A, Daniel C EMBO Mol Med. 2022; 15(2):e15931.

PMID: 36479617 PMC: 9906395. DOI: 10.15252/emmm.202215931.


Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.

Mishra A, Rathore A Mol Divers. 2022; 26(5):2613-2629.

PMID: 35000060 PMC: 8742708. DOI: 10.1007/s11030-021-10358-5.


Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.

Fullerton M, Colonne P, Dragan A, Brann K, Kurten R, Voth D mSphere. 2021; 6(4):e0044221.

PMID: 34232075 PMC: 8386451. DOI: 10.1128/mSphere.00442-21.


The Rheumatology Drugs for COVID-19 Management: Which and When?.

Atzeni F, Masala I, Rodriguez-Carrio J, Rios-Garces R, Gerratana E, La Corte L J Clin Med. 2021; 10(4).

PMID: 33669218 PMC: 7919806. DOI: 10.3390/jcm10040783.


Hydroxychloroquine in COVID-19 Patients: Pros and Cons.

Younis N, Zareef R, Al Hassan S, Bitar F, Eid A, Arabi M Front Pharmacol. 2020; 11:597985.

PMID: 33364965 PMC: 7751757. DOI: 10.3389/fphar.2020.597985.


References
1.
Baca O, Akporiaye E, Aragon A, Martinez I, Robles M, Warner N . Fate of phase I and phase II Coxiella burnetii in several macrophage-like tumor cell lines. Infect Immun. 1981; 33(1):258-66. PMC: 350684. DOI: 10.1128/iai.33.1.258-266.1981. View

2.
Yeaman M, Mitscher L, Baca O . In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob Agents Chemother. 1987; 31(7):1079-84. PMC: 174875. DOI: 10.1128/AAC.31.7.1079. View

3.
DE DUVE C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F . Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974; 23(18):2495-531. DOI: 10.1016/0006-2952(74)90174-9. View

4.
Tunstall Pedoe H . Apparent recurrence of Q fever endocarditis following homograft replacement of aortic valve. Br Heart J. 1970; 32(4):568-70. PMC: 487372. DOI: 10.1136/hrt.32.4.568. View

5.
Yeaman M, Roman M, Baca O . Antibiotic susceptibilities of two Coxiella burnetii isolates implicated in distinct clinical syndromes. Antimicrob Agents Chemother. 1989; 33(7):1052-7. PMC: 176061. DOI: 10.1128/AAC.33.7.1052. View